Inflammation and Atherosclerosis: Prospects for Clinical Trials.
作者信息
Ait-Oufella Hafid, Libby Peter
机构信息
Université Paris Cité, INSERM U970, Paris Cardiovascular Research Center (H.A.-O.), Sorbonne Université, France.
Medical Intensive Care Unit, Hôpital Saint-Antoine, AP-HP (H.A.-O.), Sorbonne Université, France.
出版信息
Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):1899-1905. doi: 10.1161/ATVBAHA.124.320155. Epub 2024 Aug 21.
Abstract
摘要
相似文献
1
Inflammation and Atherosclerosis: Prospects for Clinical Trials.炎症与动脉粥样硬化：临床试验前景
Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):1899-1905. doi: 10.1161/ATVBAHA.124.320155. Epub 2024 Aug 21.
2
Targeting the immune response in atherosclerosis: It's time for clinical trials!针对动脉粥样硬化中的免疫反应：开展临床试验的时候到了！
Arch Cardiovasc Dis. 2017 Dec;110(12):643-645. doi: 10.1016/j.acvd.2017.08.001. Epub 2017 Oct 16.
3
Inflammation and atherosclerosis: what is on the horizon?炎症与动脉粥样硬化：未来发展趋势如何？
Heart. 2020 Jan;106(1):80-85. doi: 10.1136/heartjnl-2018-314230.
4
Targeting inflammation in cardiovascular diseases. still a neglected field?靶向治疗心血管疾病中的炎症反应。这一领域仍被忽视？
Cardiovasc Ther. 2012 Aug;30(4):e189-97. doi: 10.1111/j.1755-5922.2011.00274.x. Epub 2011 Apr 1.
5
Inflammation in atherosclerosis: transition from theory to practice.动脉粥样硬化中的炎症：从理论到实践的转变。
Circ J. 2010 Feb;74(2):213-20. doi: 10.1253/circj.cj-09-0706. Epub 2010 Jan 9.
6
Inflammation and cardiovascular diseases: lessons from seminal clinical trials.炎症与心血管疾病：来自重要临床研究的启示。
Cardiovasc Res. 2021 Jan 21;117(2):411-422. doi: 10.1093/cvr/cvaa211.
7
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.炎症在动脉粥样硬化发病机制中的作用及治疗干预。
Atherosclerosis. 2018 Sep;276:98-108. doi: 10.1016/j.atherosclerosis.2018.07.014. Epub 2018 Jul 25.
8
IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.IL-17 和 Th17 细胞在动脉粥样硬化中的微妙及情境作用。
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):258-64. doi: 10.1161/ATVBAHA.114.303567. Epub 2014 Sep 18.
9
Inflammation and atherosclerosis--revisited.炎症与动脉粥样硬化——再探讨
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):170-8. doi: 10.1177/1074248413504994. Epub 2013 Oct 31.
10
Atherosclerosis revisited from a clinical perspective: still an inflammatory disease?从临床角度重新审视动脉粥样硬化：它仍是一种炎症性疾病吗？
Thromb Haemost. 2017 Jan 26;117(2):231-237. doi: 10.1160/TH16-10-0770. Epub 2016 Dec 15.
引用本文的文献
1
Prognostic implications of systemic immune-inflammation index and systemic inflammation response index in hemodialysis patients.血液透析患者全身免疫炎症指数和全身炎症反应指数的预后意义
BMC Nephrol. 2025 Jul 1;26(1):322. doi: 10.1186/s12882-025-04223-y.
2
Transcriptomic signatures of atheroresistance in the human atrium and ventricle highlight potential candidates for targeted atherosclerosis therapeutics.人类心房和心室中抗动脉粥样硬化的转录组特征突出了靶向动脉粥样硬化治疗的潜在候选物。
Biochem Biophys Rep. 2025 Apr 8;42:102007. doi: 10.1016/j.bbrep.2025.102007. eCollection 2025 Jun.
3
Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction.炎症和促消退介质在内皮功能障碍中的作用。
Basic Clin Pharmacol Toxicol. 2025 May;136(5):e70026. doi: 10.1111/bcpt.70026.
4
Atherosclerosis: A Comprehensive Review of Molecular Factors and Mechanisms.动脉粥样硬化：分子因素与机制的全面综述
Int J Mol Sci. 2025 Feb 6;26(3):1364. doi: 10.3390/ijms26031364.
5
Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?接种疫苗作为减轻心血管风险的一种有前景的方法：我们准备好接受疫苗策略了吗？
Biomolecules. 2024 Dec 20;14(12):1637. doi: 10.3390/biom14121637.
6
Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health.血管周围脂肪组织：糖尿病、肥胖症和心血管健康三联症中的核心因素。
Cardiovasc Diabetol. 2024 Dec 28;23(1):455. doi: 10.1186/s12933-024-02549-9.
7
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?评估动脉粥样硬化性心血管疾病中的炎症风险：斑块比血浆更重要？
Eur Heart J Cardiovasc Imaging. 2025 Mar 3;26(3):444-460. doi: 10.1093/ehjci/jeae314.
8
Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.晚期肺癌炎症指数对接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者全因死亡率的预测作用
J Clin Med. 2024 Oct 11;13(20):6059. doi: 10.3390/jcm13206059.
本文引用的文献
1
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.用奥替库单抗抑制氧化型低密度脂蛋白可抑制银屑病患者的冠状动脉炎症并降低残余炎症风险：一项随机、双盲、安慰剂对照的先导性试验。
Cardiovasc Res. 2024 May 29;120(7):678-680. doi: 10.1093/cvr/cvae057.
2
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans.抗 CD20 诱导 B 细胞耗竭以 BAFF 依赖的方式促进小鼠和人类的神经保护作用。
Sci Transl Med. 2024 Mar 6;16(737):eadi0295. doi: 10.1126/scitranslmed.adi0295.
3
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.调节性 T 细胞对缺血性心脏病中低剂量白细胞介素-2 的反应。
NEJM Evid. 2022 Jan;1(1):EVIDoa2100009. doi: 10.1056/EVIDoa2100009. Epub 2021 Nov 22.
4
High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction.高免疫球蛋白-M 水平对氧化特异性表位与急性心肌梗死风险降低相关。
J Lipid Res. 2023 Jun;64(6):100391. doi: 10.1016/j.jlr.2023.100391. Epub 2023 May 19.
5
The why and how of adaptive immune responses in ischemic cardiovascular disease.缺血性心血管疾病中适应性免疫反应的原因及机制
Nat Cardiovasc Res. 2022 May;1:431-444. doi: 10.1038/s44161-022-00049-1. Epub 2022 Apr 21.
6
CAR T cells produced in vivo to treat cardiac injury.体内生成的 CAR T 细胞治疗心脏损伤。
Science. 2022 Jan 7;375(6576):91-96. doi: 10.1126/science.abm0594. Epub 2022 Jan 6.
7
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect.动脉粥样硬化是人类的主要杀手，而未解决的炎症是主要嫌疑犯。
Cardiovasc Res. 2021 Nov 22;117(13):2563-2574. doi: 10.1093/cvr/cvab309.
8
Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies.动脉粥样硬化和心肌梗死中的体液免疫：从 B 细胞到抗体。
Cardiovasc Res. 2021 Nov 22;117(13):2544-2562. doi: 10.1093/cvr/cvab285.
9
The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.JAK-STAT 通路：类风湿关节炎和骨髓增殖性肿瘤中心血管疾病的新兴靶点。
Eur Heart J. 2021 Nov 7;42(42):4389-4400. doi: 10.1093/eurheartj/ehab447.
10
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6（RESCUE）：一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
Zotero 插件